Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
Standard
Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. / Martin, Silas; Feldman, Steven R; Augustin, Matthias; Szapary, Philippe; Schenkel, Brad.
in: J DERMATOL TREAT, Jahrgang 22, Nr. 3, 3, 2011, S. 138-143.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
AU - Martin, Silas
AU - Feldman, Steven R
AU - Augustin, Matthias
AU - Szapary, Philippe
AU - Schenkel, Brad
PY - 2011
Y1 - 2011
N2 - To compare the cost per responder of ustekinumab with etanercept based on data from the active comparator ACCEPT trial.
AB - To compare the cost per responder of ustekinumab with etanercept based on data from the active comparator ACCEPT trial.
KW - Humans
KW - Antibodies, Monoclonal/economics/therapeutic use
KW - Drug Costs
KW - Endpoint Determination
KW - Immunoglobulin G/economics/therapeutic use
KW - Psoriasis/drug therapy/economics
KW - Receptors, Tumor Necrosis Factor/therapeutic use
KW - Humans
KW - Antibodies, Monoclonal/economics/therapeutic use
KW - Drug Costs
KW - Endpoint Determination
KW - Immunoglobulin G/economics/therapeutic use
KW - Psoriasis/drug therapy/economics
KW - Receptors, Tumor Necrosis Factor/therapeutic use
M3 - SCORING: Journal article
VL - 22
SP - 138
EP - 143
JO - J DERMATOL TREAT
JF - J DERMATOL TREAT
SN - 0954-6634
IS - 3
M1 - 3
ER -